The brand for the Meals and Drug Administration is seen forward of a information convention on the Well being and Human Companies Headquarters in Washington, April 22, 2025.
Nathan Posner | Anadolu | Getty Photos
A key U.S. Meals and Drug Administration official who oversees vaccines and biotech remedies will step down from the company following a number of selections that raised issues inside the business.
Vinay Prasad, director of the Heart for Biologics Analysis and Analysis, will go away the FDA on the finish of April, an company spokesperson confirmed on Friday. It’s his second departure from the place: He briefly left the submit in July following backlash over his regulatory selections, and returned solely two weeks later in August.
In a submit on X, FDA Commissioner Marty Makary mentioned the FDA will appoint a successor earlier than Prasad returns subsequent month to the College of California San Francisco, the place he taught earlier than taking the FDA place final 12 months. Makary mentioned Prasad “received an amazing quantity completed” throughout his tenure on the company.
Prasad’s resolution to step down comes after criticism of the FDA mounted inside the biotech and pharmaceutical business and amongst former well being officers. Prior to now 12 months, the company has denied or discouraged the approval functions of at the least eight medication, in response to RTW Investments, after taking difficulty with information the businesses used to assist their functions. The FDA additionally initially refused to evaluation Moderna’s flu shot earlier than it later reversed course.
All of these corporations accused the FDA of reversing earlier steering concerning the proof they may use to again their functions, sparking criticism inside the business that an unreliable regulatory course of might stifle growth of medication for hard-to-treat ailments.
A former FDA official who spoke to CNBC on the situation of anonymity to talk freely on the difficulty referred to as the reversals the worst form of regulatory uncertainty as a result of corporations say they’re being informed one factor after which expertise one other.
In a press release earlier Friday, an FDA spokesperson mentioned there was “no regulatory uncertainty,” including the company “makes selections based mostly on the proof, however doesn’t make assurances about outcomes.” The spokesperson mentioned the FDA is “conducting rigorous, unbiased evaluations and never rubber-stamping approvals.”
The newest controversy got here after the FDA discouraged UniQure from making use of for expedited approval of its experimental therapy for Huntington’s illness.
The company, which underwent employees cuts and an overhaul beneath Well being and Human Companies Secretary Robert F. Kennedy Jr., has confronted broader backlash for its drug and vaccine approvals course of. Critics have apprehensive the company might stifle the event of recent remedies and threat the protection of sufferers.
The Wall Road Journal earlier reported Prasad’s departure.